56518-41-3 Usage
Description
Brodimoprim, a dihydrofolate reductase inhibitor and a structural derivative of Trimethoprim, is an aminopyrimidine with a 4-bromo-3,5-dimethoxybenzyl group replacing the hydrogen at position 5. It is an off-white to pale yellow solid and is known by the brand names Hyprim and Unitrim. Brodimoprim possesses a broad spectrum of antimicrobial activities against various Gram-positive and Gram-negative pathogens, including some strains resistant to amoxicillin. It is used for the treatment of common upper respiratory tract infections such as sinusitis and exacerbation of chronic bronchitis, and has a favorable pharmacokinetic profile with a long half-life and good tissue penetration.
Uses
Used in Pharmaceutical Industry:
Brodimoprim is used as an antimicrobial agent for the treatment of common upper respiratory tract infections, such as sinusitis and exacerbation of chronic bronchitis. It is effective against a wide range of bacterial pathogens, including some strains resistant to amoxicillin, making it a valuable addition to the arsenal of antibiotics for treating these infections.
Used in Antimicrobial Resistance Management:
Brodimoprim is used as a selective dihydrofolate reductase inhibitor to combat bacterial strains that are resistant to conventional antibiotics like amoxicillin. Its broad-spectrum antimicrobial activity and effectiveness against resistant strains contribute to the management of antimicrobial resistance in the healthcare setting.
Used in Research and Development:
As a diaminopyridine antibacterial agent, Brodimoprim is utilized in research and development for the study of its antimicrobial properties, mechanisms of action, and potential applications in the development of new antibiotics or combination therapies to address the growing challenge of antibiotic resistance.
Originator
Helsinn (Switzerland)
Check Digit Verification of cas no
The CAS Registry Mumber 56518-41-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,6,5,1 and 8 respectively; the second part has 2 digits, 4 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 56518-41:
(7*5)+(6*6)+(5*5)+(4*1)+(3*8)+(2*4)+(1*1)=133
133 % 10 = 3
So 56518-41-3 is a valid CAS Registry Number.
InChI:InChI=1/C13H15BrN4O2/c1-19-9-4-7(5-10(20-2)11(9)14)3-8-6-17-13(16)18-12(8)15/h4-6H,3H2,1-2H3,(H4,15,16,17,18)
56518-41-3Relevant articles and documents
Photocontrol of Antibacterial Activity: Shifting from UV to Red Light Activation
Wegener, Michael,Hansen, Mickel J.,Driessen, Arnold J. M.,Szymanski, Wiktor,Feringa, Ben L.
supporting information, p. 17979 - 17986 (2017/12/26)
The field of photopharmacology aims to introduce smart drugs that, through the incorporation of molecular photoswitches, allow for the remote spatial and temporal control of bioactivity by light. This concept could be particularly beneficial in the treatment of bacterial infections, by reducing the systemic and environmental side effects of antibiotics. A major concern in the realization of such light-responsive drugs is the wavelength of the light that is applied. Studies on the photocontrol of biologically active agents mostly rely on UV light, which is cytotoxic and poorly suited for tissue penetration. In our efforts to develop photoswitchable antibiotics, we introduce here antibacterial agents whose activity can be controlled by visible light, while getting into the therapeutic window. For that purpose, a UV-light-responsive core structure based on diaminopyrimidines with suitable antibacterial properties was identified. Subsequent modification of an azobenzene photoswitch moiety led to structures that allowed us to control their activity against Escherichia coli in both directions with light in the visible region. For the first time, full in situ photocontrol of antibacterial activity in the presence of bacteria was attained with green and violet light. Most remarkably, one of the diaminopyrimidines revealed an at least 8-fold difference in activity before and after irradiation with red light at 652 nm, showcasing the effective "activation" of a biological agent otherwise inactive within the investigated concentration range, and doing so with red light in the therapeutic window.
Benzylpyrimidine derivatives
-
, (2008/06/13)
N-oxides of benzylpyrimidines of the formula STR1 wherein R1, R2 and R3 are as set forth hereinafter, are described. The 2,4-diamino-5-(4-bromo-3,5-dimethoxybenzyl)-pyrimidine is also described. The compounds referred to above are useful as potentiators of the antibacterial activity of sulfonamides.
